Ovid Therapeutics Reports Q1 2026 Financial Results with Increased Net Loss and No Revenue

Ovid Therapeutics Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $16.99 million, compared to a net loss of $10.24 million for the same period in 2025. The company did not generate any revenue during the quarter, a significant decrease from the $130,000 reported in the prior year, which was attributed to a licensing agreement. Operating expenses increased to $17.85 million from $12.68 million year-over-year, driven primarily by a rise in research and development costs, which totaled $11.18 million, up from $6.66 million in the previous year.

The company's total assets as of March 31, 2026, stood at $225.63 million, a notable increase from $150.93 million at the end of 2025. This growth was largely due to a substantial rise in cash and cash equivalents, which surged to $94.06 million from $13.15 million. The increase in cash was bolstered by recent financing activities, including a private placement that raised $56.2 million in March 2026 and the exercise of Series A warrants, which contributed an additional $53.9 million. Ovid's accumulated deficit reached $338.7 million as of the end of the quarter.

In terms of strategic developments, Ovid Therapeutics has been actively pursuing clinical trials for its drug candidates, including OV329 and OV4071, which are aimed at treating neurological disorders. The company received approval to initiate a Phase 1 clinical trial for OV4071 in Australia, marking a significant step in its development pipeline. Additionally, Ovid has been expanding its capital base through various financing mechanisms, including an at-the-market offering program, which has provided approximately $2.4 million in net proceeds during the quarter.

Operationally, Ovid's employee headcount has seen fluctuations, impacting general and administrative expenses, which rose to $6.67 million from $6.02 million year-over-year. The company continues to focus on building its research and development capabilities while managing costs associated with its clinical programs. As of March 31, 2026, Ovid had a working capital of $144.4 million, which management believes will be sufficient to fund operations for at least the next 12 months.

Looking ahead, Ovid Therapeutics anticipates continued operating losses as it invests in the development of its drug candidates. The company remains dependent on securing additional funding through equity offerings, collaborations, and licensing agreements to support its ongoing research and development efforts. The management has expressed confidence in its ability to navigate the financial landscape, although it acknowledges the inherent risks and uncertainties associated with the biotechnology industry, including regulatory approvals and market conditions.